iBio, Inc. (IBIO)
IBIO Stock Price Chart
Explore iBio, Inc. interactive price chart. Choose custom timeframes to analyze IBIO price movements and trends.
IBIO Company Profile
Discover essential business fundamentals and corporate details for iBio, Inc. (IBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Aug 2008
Employees
16.00
Website
https://www.ibioinc.comCEO
Martin B. Brenner
Description
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
IBIO Financial Timeline
Browse a chronological timeline of iBio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Apr 2026
Upcoming earnings on 9 Feb 2026
Upcoming earnings on 19 Sept 2025
EPS estimate is -$0.30, while revenue estimate is $100.00K.
Earnings released on 2 May 2025
EPS came in at -$0.49 falling short of the estimated -$0.39 by -25.64%.
Earnings released on 10 Feb 2025
EPS came in at -$0.48 falling short of the estimated -$0.45 by -6.67%, while revenue for the quarter reached $200.00K .
Earnings released on 12 Nov 2024
EPS came in at -$0.46 matching the estimated -$0.46.
Earnings released on 25 Sept 2024
EPS came in at -$0.91 falling short of the estimated -$0.47 by -93.62%, while revenue for the quarter reached $175.00K .
Earnings released on 13 May 2024
EPS came in at -$0.71 .
Earnings released on 9 Feb 2024
EPS came in at -$2.42 .
Stock split effective on 29 Nov 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2023
EPS came in at -$4.20 , while revenue for the quarter reached $50.00K .
Earnings released on 27 Sept 2023
EPS came in at $0.26 surpassing the estimated -$0.41 by +163.41%.
Earnings released on 11 May 2023
EPS came in at -$6.61 falling short of the estimated -$3.42 by -93.36%, while revenue for the quarter reached $200.00K , meeting expectations.
Earnings released on 14 Feb 2023
EPS came in at -$21.60 surpassing the estimated -$146.90 by +85.30%.
Earnings released on 14 Nov 2022
EPS came in at -$2.05 falling short of the estimated -$1.85 by -10.81%, while revenue for the quarter reached $56.00K , missing expectations by -90.67%.
Earnings released on 11 Oct 2022
EPS came in at -$1.96 surpassing the estimated -$2.12 by +7.55%, while revenue for the quarter reached $61.00K , missing expectations by -75.60%.
Stock split effective on 10 Oct 2022
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2022
EPS came in at -$30.00 falling short of the estimated -$1.25 by -2.30K%, while revenue for the quarter reached $1.94M , beating expectations by +871.50%.
Earnings released on 14 Feb 2022
EPS came in at -$25.00 falling short of the estimated -$1.00 by -2.40K%, while revenue for the quarter reached $168.00K , missing expectations by -32.80%.
Earnings released on 15 Nov 2021
EPS came in at -$20.00 falling short of the estimated -$1.25 by -1.50K%, while revenue for the quarter reached $211.00K , missing expectations by -29.67%.
Earnings released on 27 Sept 2021
EPS came in at -$25.00 , while revenue for the quarter reached $491.00K .
Earnings released on 17 May 2021
EPS came in at -$20.00 falling short of the estimated -$1.25 by -1.50K%, while revenue for the quarter reached $765.00K , missing expectations by -16.67%.
Earnings released on 16 Feb 2021
EPS came in at -$20.00 falling short of the estimated -$1.00 by -1.90K%, while revenue for the quarter reached $705.00K , meeting expectations.
Earnings released on 16 Nov 2020
EPS came in at -$25.00 falling short of the estimated -$2.00 by -1.15K%, while revenue for the quarter reached $410.00K , missing expectations by -27.27%.
Earnings released on 13 Oct 2020
EPS came in at -$8.03 falling short of the estimated -$1.25 by -542.54%, while revenue for the quarter reached $1.12M .
IBIO Stock Performance
Access detailed IBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.